Loading
NASDAQHealthcareMedical - Devices
Latest quote
$104.99
−$2.21 · -2.06%
iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.
Previous close
$104.99
−$2.21 · -2.06%
Pre-market
$103.5
−$1.49 · -1.42%
Oct 8, 5:22 AM ET
Regular session · ET · Market data may be delayed.
iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.
Day range
Current $104.99
52-week range
Current $104.99
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
78
Undervalued
Sentiment
66
Bullish
Risk
59
Elevated Risk
Momentum
34
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.
Day range
Current $104.99
52-week range
Current $104.99
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 747.14M USD | 591.84M USD | 492.68M USD | 410.92M USD | 322.83M USD |
| Cost of goods sold | 219.89M USD | 184.31M USD | 160.88M USD | 129.29M USD | 109.26M USD |
| Gross profit | 527.25M USD | 407.53M USD | 331.81M USD | 281.63M USD | 213.57M USD |
| Research and development | 84.61M USD | 103.83M USD | 60.24M USD | 46.61M USD | 38.67M USD |
| Selling, general, and administrative | 479.45M USD | 418.57M USD | 385.65M USD | 322.2M USD | 274.84M USD |
| Operating expenses | 564.06M USD | 523.04M USD | 456.97M USD | 395.42M USD | 313.51M USD |
| Interest income | 21.52M USD | 21.94M USD | 6.16M USD | 2.35M USD | 118K USD |
| Interest expense | 13.15M USD | 12.82M USD | 3.65M USD | 4.14M USD | 1.17M USD |
| Depreciation and amortization | 26.48M USD | 25.78M USD | 22.14M USD | 19.61M USD | 16.59M USD |
| Operating income | −36.81M USD | −115.51M USD | −125.16M USD | −113.78M USD | −99.94M USD |
| Net income | −44.55M USD | −113.29M USD | −123.41M USD | −116.16M USD | −101.36M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$174.88
66.57% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI122.4M0.01%2.3T USD0.03%$381.03-0.40%
iShares Russell 2000 ETFIWM92.42M0.12%78.56B USD0.19%$277.7-1.29%
Vanguard Morningstar Small-Cap ETFVB88.45M0.05%185.3B USD0.03%$286.98-1.41%
Vanguard Morningstar Small-Cap Growth ETFVBK50.85M0.11%44.7B USD0.05%$342.24-1.50%
Vanguard Extended Market ETFVXF45.45M0.05%95.4B USD0.05%$233.49-1.56%
iShares Russell 2000 Growth ETFIWO33.24M0.23%14.25B USD0.24%$355.37-1.43%
Vanguard Russell 2000 ETFVTWO22.65M0.12%18B USD0.06%$112.21-1.26%
Schwab U.S. Small-Cap ETFSCHA18.35M0.08%22.01B USD0.03%$32.61-1.47%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
